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The standard management of autoimmune hepatitis (AIH) is based on 
corticosteroids, alone or in combination with azathioprine. Second-line treatments 
are needed for patients who have refractory disease. However, high-quality data 
on the alternative management of AIH are scarce.
AIM 
To evaluate the efficacy and safety of tacrolimus and mycophenolate mofetil 
(MMF) and the quality of evidence by using the Grading of Recommendations 
Assessment, Development and Evaluation approach (GRADE).
METHODS 
A systematic review and meta-analysis of the available data were performed. We 
calculated pooled event rates for three outcome measures: Biochemical remission, 
adverse events, and mortality, with their corresponding 95% confidence intervals 
(CI).
RESULTS 
The pooled biochemical remission rate was 68.9% (95%CI: 60.4-76.2) for 
tacrolimus, and 59.6% (95%CI: 54.8-64.2) for MMF, and rates of adverse events 
were 25.5% (95%CI: 12.4-45.3) for tacrolimus and 24.1% (95%CI: 15.4-35.7) for 
MMF. The pooled mortality rate was estimated at 11.5% (95%CI: 7.1-18.1) for 
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tacrolimus and 9.01% (95%CI: 6.2-12.8) for MMF. Pooled biochemical remission 
rates for tacrolimus and MMF in patients with intolerance to standard therapy 
were 56.6% (CI: 43.4-56.6) vs 73.5% (CI: 58.1-84.7), and among non-responders 
were 59.1% (CI: 48.7-68.8) vs 40.8% (CI: 32.3-50.0), respectively. Moreover, the 
overall quality assessments using GRADE proved to be very low for all our 
outcomes in both treatment groups.
CONCLUSION 
Tacrolimus and MMF are in practice considered effective for patients with AIH 
who are non-responders or intolerant to first-line treatment, but we found no 
high-quality evidence to support this statement.
Key Words: Autoimmune hepatitis; Efficacy; Grading of Recommendations Assessment, 
Development and Evaluation approach; Systematic review; Meta-analysis; Second-line
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: There is no consensus in the literature on which second-line treatment is superior 
in autoimmune hepatitis (AIH). This is the first systematic review and meta-analysis to 
compare the efficacy and safety of tacrolimus and mycophenolate mofetil (MMF) as 
second-line treatments in AIH. We also evaluated the quality of evidence for adding to the 
clinical guidelines for routine practice. We conclude that tacrolimus and MMF are 
considered effective for patients who are non-responders or intolerant to first-line 
treatment, but the quality of evidence is not high and it is questionable if these results 
should be added to clinical guidelines for AIH.
Citation: Abdollahi M, Khalilian Ekrami N, Ghojazadeh M, Boezen HM, Somi M, Alizadeh 
BZ. Tacrolimus and mycophenolate mofetil as second-line treatment in autoimmune hepatitis: 





Autoimmune hepatitis (AIH) is a rare, chronic, inflammatory liver disease, 
characterized by elevated transaminase and immunoglobulin G levels, positive 
autoantibodies and interface hepatitis at liver histology[1,2]. It affects people of all ages 
and can lead to cirrhosis, hepatic failure, liver transplantation, and death[3]. Despite the 
availability of effective treatment and an evident good response to therapy, patients 
have a poor prognosis if the disease is left untreated or is treated suboptimally[4,5].
Standard first-line treatment of AIH is based on prednisolone, either given alone or 
in combination with azathioprine (AZA)[6]; these treatments lead to remission in 80% 
of patients[7,8]. However, about 20% of patients are refractory to standard treatment; 
this could be a result of suboptimal response, including treatment failure or 
incomplete response, or because patients are intolerant to standard treatment due to 
side-effects[8]. Thus, several second-line treatment modalities have been introduced for 
refractory AIH patients, including tacrolimus, mycophenolate mofetil (MMF), 
cyclosporine and budesonide[6-9]. Tacrolimus is a calcineurin inhibitor, which exerts 
more potent immunosuppressive effects on CD4+ T helper cells with fewer cosmetic 
side-effects. MMF is a purine antagonist similar to AZA, but it has more potent 
immunosuppressive properties and is better tolerated than AZA[10,11]. Tacrolimus and 
MMF have empirically been used the most, as alternative medications based on the 
American Association for the Study of Liver Diseases (AASLD) practice[8]. They are the 
most used drugs based on expert opinions[12]. Nevertheless, the efficacy and 
superiority of these interventions compared to using high-dose prednisolone and AZA 
has not been reported[8]. Furthermore, there is a lack of primary consensus on overall 
drug side-effects and disease mortality, at least for tacrolimus.
The accumulating but still sparse data indicate that refractory AIH patients do 
respond to these alternative treatments[13]. However, there is no firm evidence of their 
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effectiveness. First, there has been no randomized clinical trial (RCT) directly 
comparing these two medications to each other. Second, the available data are mainly 
based on small series of patients or case reports, from only a few centers, and little 
quality assessment has been performed. Thus, the translation of these findings to a 
guideline is questionable[14]. Third, two recent meta-analyses, which summarized the 
effect of the two medications in AIH, had a number of shortcomings. One study 
focused on improvement of aminotransferases rather than biochemical remission[15], 
while the second study included some (n = 12), but not all of the previously published 
studies related to MMF, and had analytical issues, such as reporting incorrect 
heterogeneity, ignoring existing publication bias, and reporting an incorrect overall 
mortality rate[16]. Therefore, their conclusions did not appear to be well supported by 
their results.
Furthermore, there is no systematic review or meta-analysis to compare tacrolimus 
with MMF as a second-line treatment in refractory AIH, or to evaluate the adverse 
effects, safety profile, and mortality rate of tacrolimus as a second-line treatment in 
refractory AIH. Recently two studies reported on the efficacy of tacrolimus[17] and 
MMF[18] as second-line treatment in AIH; these both need to be added to the overall 
assessment of the efficacy of these two medications in refractory AIH. In the absence of 
classical RCTs, and the shortcomings of previous investigations, there were still no 
comprehensive studies to evaluate the superiority of these two drugs for refractory 
AIH patients. The main question is whether there is sufficient high-quality scientific 
evidence to adapt the clinical guidelines.
Therefore, to study whether tacrolimus and MMF are superior alternative 
treatments, we firstly performed a systematic review and meta-analysis on the efficacy 
and safety of these treatments as second-line treatment in AIH patients. We also 
critically checked whether the quality of evidence, assessed by the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) approach[19,20], 
was sufficient to support adapting the clinical guidelines for routine practice.
MATERIALS AND METHODS
Protocol and registration 
This study was conducted according to the guidelines in Meta-analysis of 
Observational Studies in Epidemiology (MOOSE)[21].
Information sources and search strategies
We reviewed the literature, focusing on our aim to identify, appraise, select and 
synthesize all the high-quality evidence available. To identify published articles and 
ongoing studies, we conducted a comprehensive search of electronic databases, 
including PubMed, EMBASE and Cochrane Central Register, with additional 
searching of the clinical trials website at www.clinicaltrials.gov. All databases were 
searched from their inception through October 2019, with no language restrictions. 
The search strategy was designed with the help of an experienced medical librarian 
and with input from investigators. Search terms were selected using Medical Subject 
Headings (Mesh) terms, including (but not limited to) "Hepatitis, Autoimmune", 
"Tacrolimus", "Mycophenolic Acid” and "Drug Resistance". In addition, to minimize 
the chance of missing any study, the reference lists of the included articles were 
searched individually for additional studies.
Eligibility criteria
We included studies which met the following criteria: Randomized or non-
randomized controlled trials, case series of any duration, cohort studies, and reports 
that provided data on patients over 18 years with AIH who failed or were unable to 
tolerate first-line therapy prior to liver transplantation. Studies that used tacrolimus 
and/or MMF had to report on the disease outcomes studied. We excluded studies that 
reported data for AIH in children or adolescents aged ≤ 18 years, because they have a 
more aggressive disease, often with a more acute presentation[22] and they therefore 
need a different management[23]; or that reported data on patients who had had a liver 
transplantation.
Outcomes
Biochemical remission was the primary outcome for our study. This was defined as the 
disappearance of symptoms, normal serum bilirubin, γ-globulin and serum 
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aminotransferase levels[8]. Secondary outcomes were the occurrence of adverse events 
and mortality. We evaluated the available data for these outcomes per individual in 
the studies included in our analysis. For example, if γ-globulin levels were not 
described in a certain study, we used the variables available, such as clinical and 
biochemical variables, to reach the most likely definition of remission for that study.
Some studies reported biochemical remission depending on the reason for using 
second-line therapy (intolerance vs non-response). Thus, we performed a subgroup 
analysis in non-responders and those intolerant to standard therapy to compare the 
effect of tacrolimus and MMF in the two different groups that used the drug as 
second-line therapy.
Study selection and data extraction
After excluding duplicated reports, the reports included in our analysis were reviewed 
on the basis of their title and abstract by two independent reviewers (MA, MG). 
Thereafter, the full texts of selected reports were retrieved and independently assessed 
by both reviewers to identify which studies satisfied our inclusion criteria. 
Discrepancies between the two reviewers regarding eligibility were solved by jointly 
looking at the study in question. If no consensus was reached, a third reviewer (BZA) 
was consulted. Agreement was measured using inter-rater reliability (Cohen's Kappa).
Next, we extracted data on each study: Study characteristics (including the surname 
of the first author and year of publication), patients’ characteristics (including mean 
age and number of patients), intervention characteristics (including duration of 
applied therapy and length of follow-up), as well as data on our primary and 
secondary outcome measures.
Methodological quality
The two reviewers independently rated the methodological quality of each study 
using the GRADE tool for study-level assessments of risk of bias[19,20]. Specifically, the 
domains assessed for risk of bias included: Failure to develop and apply appropriate 
eligibility criteria (inclusion of control population), flawed measurement of either 
intervention or outcome, failure to adequately control confounding, and incomplete 
follow-up.
GRADE quality assessment
The GRADE approach was used to assess the quality of evidence for primary and 
secondary outcomes[20,21]. It provides guidance for rating the quality of evidence and 
grading the strength of recommendations by asking a clear question for each outcome. 
The level of evidence was graded as high or moderate when it was derived from RCTs, 
and as low or very low if it was derived from observational studies. The level of 
evidence could be upgraded or downgraded depending on the quality of the study. 
The criteria provided for possibly downgrading the quality of evidence include: Risk 
of bias, publication bias, indirectness, imprecision and inconsistency. The three main 
reasons for upgrading the quality of evidence include: Large effect size, dose response 
gradient, and all plausible residual confounders increase confidence in the estimated 
effect. Each study can be given up to two points for every domain that begins with a 
high rating that is later downgraded one level (judged to have serious concerns) and 
two levels (if concerns are very serious). These evaluations result in one of four quality 
ratings – high, moderate, low and very low – that reveal the degree of confidence one 
can have in the available evidence correctly reflecting the theoretical true effect of the 
intervention. GRADE ratings are given as described by Balshem et al[24], and are 
adjudicated as high (we are very confident that the true effect lies close to that of the 
estimate of the effect), moderate (the true effect is likely to be close to the estimate of 
the effect, but there is a possibility that it could be substantially different), low (our 
confidence in the effect estimate is limited, i.e., the true effect may be substantially 
different from the estimate of the effect), or very low (we have very little confidence in 
the effect estimate, i.e., the true effect is likely to be substantially different from the 
estimate of effect).
Statistical analysis
Several studies reported the median, minimum and maximum values. Hence, in order 
to be able to combine the results, we deducted the sample mean and standard 
deviation (SD) using Wan et al ’s[25] method for those studies. We estimated pooled 
event rates with corresponding 95% confidence intervals (CI) using the inverse 
variance method per analyzed outcome. We applied random effects models whenever 
there was significant heterogeneity between studies.
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Q test, the associated P value (P < 0.10) and also the I2 test were used to assess 
heterogeneity among the included studies. According to Higgins et al[26] I2 < 40% 
indicates low heterogeneity, 30% < I2 < 60% indicates moderate heterogeneity, while 
50% < I2 < 90% may represent substantial heterogeneity, and > 75% considerable 
heterogeneity. Publication bias was evaluated using funnel plots and Egger’s test for 
asymmetry with 95%CI, with the results considered to indicate potential small study 
effects when P < 0.10[27]. Comprehensive meta-analysis software version 3.0 was used 
for our statistical analyses[28]. The statistical methods of this study were reviewed by 
Dr. Milada Småstuen Cvancarova from Oslo Metropolitan University, Oslo, Norway.
RESULTS
Study selection
The initial database search yielded 243 valid hits, of which 71 were duplicates and 
removed (Figure 1). The titles and abstracts of the remaining 172 citations were 
screened, leading to exclusion of a further 87 citations. The remaining 85 articles were 
assessed for relevance to our outcomes of interest. A full text review led to 64 articles 
being excluded. Overall, 21 studies met our eligibility criteria. Cohen's Kappa for inter-
rater reliability between the two reviewers was 0.88. Thus, 21 unique observational 
studies[17,18,29-47] were eligible to be included in the meta-analysis and to be evaluated on 
the scientific quality of data using GRADE. The search results are summarized in 
Figure 1.
Study characteristics
Nine studies reported data on tacrolimus and 16 on MMF. Their geographical 
distribution was diverse, with studies carried out in the United States, Canada, United 
Kingdom, Denmark, Germany, the Netherlands, Belgium, Sweden, China, India and 
Australia. Most studies included middle-aged subjects who were predominantly 
female. In the tacrolimus studies, the average follow-up time was longer than in the 
MMF studies (51 mo vs 38 mo), patients were younger (mean age 37.8 years vs 42.8 
years) and more females (73.3% vs 71.2%) were observed. Applied dosages varied 
between 2.0 and 6.0 mg daily of tacrolimus, and between 0.5 g and 2.0 g daily of MMF. 
The basic characteristics of the studies are presented in Table 1.
Methodological quality of the studies
For each of the 21 included studies, the methodological quality (risk of bias) was 
assessed and downgraded for the presence of bias using the GRADE risk of bias tool 
on a scale of 0 to -2. Four studies were rated as having no risk of bias (scored as 0), 16 
studies had a serious risk of bias (scored as -1) and the remaining two had a very 
serious risk of bias (scored as -2). The details of the assessment of the methodological 
quality of the studies is reported in Table 2 and Figure 2-4.
Pooled prevalence of biochemical remission
In total, we included 584 patients with AIH who were unable to tolerate or respond to 
first-line therapy. In 157 patients treated with tacrolimus, the overall pooled 
prevalence of biochemical remission was 68.9% (95%CI: 60.4-76.2), and in 427 patients 
with MMF 59.6% (95%CI: 54.8-64.2) (Figure 3 and 4).
Significant moderate heterogeneity was found among the 21 studies in the meta-
analysis for tacrolimus and MMF (Q = 16.25 vs 29.72, df = 8 vs 15, P < 0.0001), 
respectively. According to I2 values for the tacrolimus and MMF groups, 
approximately 50.8% vs 49.5% respectively, the variability in effect estimates was due 
to the heterogeneity between the studies rather than a sampling error or chance. 
Overall quality assessments using GRADE were very low for biochemical remission in 
both intervention groups (Table 2).
Egger’s regression test for tacrolimus (intercept = 0.02, 95%CI: -2.14 to 2.18; P = 0.98) 
and for MMF (intercept = -0.36, 95%CI: -1.77 to 1.06; P = 0.59) did not show statistically 
significant asymmetry of the funnel plots, suggesting that publication bias was 
unlikely in both intervention groups (Figure 5).
Overall, 15 studies specified response rates according to the reason for using 
tacrolimus or MMF. In patients with intolerance to standard therapy, the pooled 
biochemical remission rate for tacrolimus was 56.6% (CI: 43.4-56.6), and 73.5% (CI: 
58.1-84.7) for MMF. Among non-responders 59.1% (CI: 48.7-68.8) did respond to 
tacrolimus, while 40.8% (CI: 32.3-50.0) responded to MMF.
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Table 1 Baseline characteristics and summary of findings of the 21 studies included in our meta-analysis of second-line treatments for 













Zolfino et al[29] 2002 United Kingdom 5 3/5 28.4 ± 
12.26
Retrospective 2/5 (40) NR 2-4 
Aqel et al[30] 2004 United States 11 10/11 63 Retrospective 10/11 (91) 161 3.0
Chatur et al[31] 2005 Canada 3 NR NR Retrospective 0/3 (0) 26.5 
(10–54)
2-4 
Larsen et al[32] 2007 Denmark 9 8/9 36 ± 
16.06
Retrospective 9/9 (100) 21.25 ± 
8.37
2 (2-4) 
Yeoman et al[33] 2011 United Kingdom 9 5/9 39.5 ± 
18.07
Retrospective 7/9 (77.8) NR NR
Tannous et al[34] 2011 United States 13 10/13 40.6 ± 
12.5
Retrospective 12/13 (92.3) 1-65 2-6 
Than et al[35] 2016 German, United 
Kingdom
17 11/17 34.5 ± 
15.03
Retrospective 9/17 (53) 84 ± 53.45 2 (0.5-5)1
Efe et al[36] 2017 Europe, United States, 
Canada, and China
80 60/80 34.7 ± 
11.78
Retrospective 58/80 (72.5) 85.75 ± 
37.83
3 (0-6)1
Pape et al[17] 2020 Belgium, Netherlands 10 8/10 38 ± 
13.67
Retrospective 5/10 (50) 14.5 ± 6.47 3.5 ± 1.72
MMF
Richardson et al[37] 2000 United Kingdom 7 6/7 27.28 ± 
10.45
Retrospective 5/7 (71.4) 43 ± 13.92 2 
Zolfino et al[29] 2002 United Kingdom 2 1/2 17.5 ± 
2.12
Retrospective 0/2 (0) NR 2 
Devlin et al[38] 2004 Canada 5 4/5 54 ± 
2.10.83
Retrospective 5/5 (100) NR 1-2 
Chatur et al[31] 2005 Canada 11 NR NR Retrospective 7/11 (63.6) 26.5 
(10–54)
0.5-2 
Czaja et al[39] 2005 United States 7 NR NR Retrospective 0/7 (0) 19 ± 7 0.5-3 
Inductivo-Yu 
et al[40]
2007 United States 15 11/15 60 ± 15 Retrospective 11/15 (73.3) 41 2 
Hlivko et al[41] 2008 United States 12 NR NR Retrospective 8/12 (66.7) NR 0.5-2 
Hennes et al[42] 2008 Germany 36 28/36 41.5 ± 
13.24




Wolf et al[43] 2009 United States 16 NR NR Retrospective 12/16 (75) NR 1-2 
Sharzehi et al[44] 2010 United States 17 13/17 50 Retrospective 8/17 (48) 12 0.5-2 
Yeoman et al[33] 2011 United Kingdom 2 1/2 31.5 ± 
19.51
Retrospective 1/2 (50) NR NR
Baven-Pronk 
et al[45]
2011 The Netherlands 30 24/30 NR Retrospective 14/30 (46.7) 39.5 ± 
22.51
0.5-3
Jothimani et al[46] 2014 India, United Kingdom 19 16/19 52.25 ± 
16.52
Retrospective 14 /19 (73.6) 45.4 ± 
21.13
1-2 
Roberts et al[47] 2018 Australia 105 92/105 52.5 ± 
3.65




Efe et al[36] 2017 Europe, United States, 
Canada, and China
121 96/121 41.25 ± 
13.45





2019 Sweden 22 12/22 50 ± 
12.57
Retrospective 10/22 (45.5) 71 (10-54)1 2.0 
(1.0–2.5)1
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1Median.
2Mean dose in tacrolimus studies is defined as mg/d and in mycophenolate mofetil studies is defined as g/d. NR: Not reported; MMF: Mycophenolate 
mofetil.
Table 2 Summary of findings and quality assessment of evidence per our outcomes of interest using the Grading of Recommendations 
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16 Observational Serious1 Serious2 Not 
serious









13 Observational Serious1 Serious2 Not 
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1Failure to develop and apply appropriate eligibility criteria.
2Statistically significant heterogeneity. MMF: Mycophenolate mofetil.
Pooled event rate of adverse events
Frequencies and percentages of reported adverse events were not adequately 
mentioned in five studies (two studies in tacrolimus[29,33] and three studies in 
MMF[29,33,39]). Patients given tacrolimus had a number of adverse events, in which 
neurologic symptoms and gastrointestinal side-effects were the most common; 22 
patients had to discontinue the drug due to adverse events. The most common adverse 
events associated with MMF were gastrointestinal side-effects and leukopenia, which 
led to 46 patients discontinuing the drug.
The pooled adverse event rate for tacrolimus was 25.5% (95%CI: 12.4-45.3) and for 
MMF was 24.1% (95%CI: 15.4-35.7) (Supplementary Figures 1 and 5). There was 
substantial significant heterogeneity among the studies in both intervention groups 
yield an I2 = 66.73% (Phet = 0.006) for tacrolimus and 74.24% (Phet = 0.001) for MMF. 
Overall quality assessments using GRADE were very low for adverse events in both 
intervention groups (Table 2).
Egger’s regression test for tacrolimus (intercept = 0.87, 95%CI: -3.35 to 5.09; P = 0.62) 
and for MMF (intercept = -0.36, 95%CI: -2.93 to 2.22, P = 0.77) did not show statistically 
significant asymmetry of the funnel plot, suggesting that publication bias was unlikely 
(Supplementary Figures 2 and 6).
Pooled mortality rate
The studies reported 14 deaths occurring in a total of 157 patients (8.9%) treated with 
tacrolimus and 22 deaths in 427 patients (5.2%) treated with MMF. The pooled 
mortality rate was 11.5% (95%CI: 7.1-18.1) in the tacrolimus group and 9% (95%CI: 6.2-
12.8) in the MMF group (Supplementary Figures 3 and 7). There was no significant 
heterogeneity between studies for all-cause mortality in either intervention group, 
yielding an I2 = 0% (Phet = 0.71) for tacrolimus and 12.46% (Phet = 0.31) for MMF. Overall 
quality assessments using GRADE were very low for mortality in both intervention 
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Figure 1 PRISMA flow diagram of the articles retrieved by systematic literature search. AIH: Autoimmune hepatitis.
Figure 2  Assessment of methodological quality (risk of bias) of articles identified in the systematic literature search and included in our 
meta-analysis.
groups (Table 2).
Egger’s regression test for tacrolimus (intercept = -0.35, 95%CI: -1.63 to 0.93, P = 
0.54) did not show statistically significant asymmetry of the funnel plot, suggesting 
that publication bias was unlikely. In the MMF group (intercept = -1.08, 95%CI: -1.86 to 
-0.30, P = 0.01) there was statistically significant asymmetry of the funnel plot, 
suggesting there was a publication bias here (Supplementary Figures 4 and 8).
GRADE quality assessment of evidence
The GRADE quality scoring across the studies per outcome is summarized in Table 2. 
We rated the overall quality of the evidence to be very low for biochemical remission, 
due to inconsistency (statistically significant heterogeneity) and study limitations (risk 
of bias in 17 studies); as very low for adverse events due to inconsistency (statistically 
significant heterogeneity) and study limitations (risk of bias in 14 studies); and as very 
low for mortality owing to study limitations (risk of bias in 17 studies).
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Figure 3 The pooled event rate of biochemical remission in the tacrolimus group with risk of bias assessment per study. Heterogeneity: Q = 
16.25, degree of freedom = 8 (P = 0.039); I2 = 50.76%. Test for overall effect: Z = 4.21 (P < 0.0001). A: Failure to develop and apply appropriate eligibility criteria 
(inclusion of control population); B: Flawed measurement of both exposure and outcome; C: Failure to adequately control confounding; D: Incomplete follow-up. CI: 
Confidence interval.
Figure 4 The pooled event rate of biochemical remission in the mycophenolate mofetil group with risk of bias assessment per study. 
Heterogeneity: Q = 29.72, degree of freedom = 15 (P = 0.013); I2 = 49.52%. Test for overall effect: Z = 3.85 (P = 0 < 0.0001). A: Failure to develop and apply 
appropriate eligibility criteria (inclusion of control population); B: Flawed measurement of both exposure and outcome; C: Failure to adequately control confounding; 
D: Incomplete follow-up. CI: Confidence interval.
DISCUSSION
In our comprehensive analysis of 21 observational studies, comprising a total of 584 
patients, we first evaluated the efficacy and safety of tacrolimus and MMF as a second-
line treatment for patients with AIH. Two of our key findings are that tacrolimus is 
efficient in treating patients who did not respond to first-line treatments, yielding a 
biochemical remission rate of 59.1%, while MMF is considered effective for patients 
who are intolerant to the first-line therapy, yielding a biochemical remission rate of 
73.5%.
In our critical assessment of the quality of the evidence using the GRADE approach, 
and in the absence of RCTs, we graded the quality of the observational studies as poor 
both for tacrolimus and MMF. Using the current evidence to develop therapeutic 
guidelines for these two medicines is therefore questionable. The three major strengths 
of our study are: The comprehensive search performed to trace all the eligible studies, 
our use of the rigorous methods given by the Cochrane Collaboration for data 
extraction, analysis and synthesis, and our assessment of risk of bias and the quality of 
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Figure 5  The publication bias of included studies for biochemical remission in (A) tacrolimus and (B) mycophenolate mofetil groups.
evidence using the GRADE approach.
One of the important aspects of an unbiased meta-analysis should be the 
performance of a comprehensive search for published studies. Previous meta-
analyses[15,16] had several methodological problems, such as including studies on the 
treatment of naive AIH patients[15], not including all previously published studies[16], 
statistical errors such as reporting incorrect heterogeneity, not reporting on publication 
bias, and incorrect mortality rate[16]. Thus, their estimates on the efficacy of tacrolimus 
and MMF as second-line treatment modalities for AIH may not be accurate, and their 
conclusions on the superiority of these drugs may not be truly supported by their 
results. In the light of these shortcomings, we decided to perform a systematic review 
and meta-analysis of all the reported studies to date.
Biochemical remission
We found tacrolimus and MMF to be efficient interventions in treating patients who 
were non-responders or intolerant to first-line treatment. In our meta-analysis, we 
found a 59.1% biochemical remission rate in patients who were non-responsive to first-
line therapy. The results from previous studies varied widely: Some found tacrolimus 
to be completely effective on biochemical remission[30,32,34], whereas others reported low 
remission rates[29,31]. In three studies, tacrolimus had a biochemical remission rate of 
more than 90% in refractory AIH patients[30,32,34], while another study reported a 
remission rate of 77% in refractory AIH patients[33]. More recently, Than et al[35] 
reported that 53% of refractory AIH patients responded to tacrolimus.
Similarly, previous meta-analysis has focused on the improvement of 
aminotransferases rather than biochemical remission, and reported an average rate of 
improvement of 78.7%[15]. Our study suggests tacrolimus can improve biochemical 
remission in 68.9% of patients with refractory AIH who responded to tacrolimus as 
second-line therapy.
However, current data concerning the efficacy of MMF in patients intolerant to first-
line therapy are inconclusive. We found a 73.5% biochemical remission rate for MMF 
taken by patients intolerant to first-line treatment. Our findings agree with those of 
previous studies[38,44,45] that state that biochemical remission is significantly more 
common in intolerant AIH patients compared to those who were non-responsive. 
Some studies found MMF to be effective in intolerant patients, whereas other studies 
reported biochemical remission rates of less than 25% in non-responders[39,42,44-46]. 
Likewise, a recent meta-analysis[16], although it had various limitations, found a pooled 
remission rate much greater (82%) in patients intolerant to standard therapy compared 
to non-responders (32%). The difference in MMF biochemical remission rates in 
patients intolerant to first-line treatment in our study compared to a previous meta-
analysis[16] (73.5% vs 82%) is likely due to their incomplete or selective inclusion of 
published studies. Given these data, MMF does seem to be a useful alternative therapy 
for AIH patients who are intolerant to first-line treatment.
Safety and side-effects
Tacrolimus: There are few reports of side-effects of tacrolimus in AIH patients. To 
date, our study is the first to evaluate the pooled adverse event rate and safety profile 
of tacrolimus as a second-line treatment for refractory AIH. The pooled adverse event 
rate for tacrolimus was 25.5% in our study. Overall, neurotoxicity and gastrointestinal 
issues are the most common side-effects, while diabetes mellitus, nephrotoxicity, 
pruritus and alopecia may also occur[48]. Previous studies showed that the high serum 
tacrolimus levels may have led to the rise in creatinine level and subsequent 
nephrotoxicity. The latest studies suggest using a lower dose of tacrolimus to maintain 
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blood levels below 6 ng/dL, to prevent probable renal complications or significant 
changes in creatinine level[32]. Monitoring the drug level to maintain a satisfactory dose 
and prevent nephrotoxicity is a crucial aspect. Thus, physicians must remain cautious 
when prescribing tacrolimus at a high dosage. Other reasons for withdrawing 
tacrolimus treatment include hemolytic uremic syndrome, development of squamous 
cell carcinoma, intense abdominal pain, non-compliance, overlap with primary 
sclerosing cholangitis and/or primary biliary cirrhosis, and orthotopic liver 
transplantation. To date, tacrolimus seems to be a reasonable alternative drug for non-
responders, but there is no uniform guideline to explain the dosing schedule and an 
acceptable safety profile, nor an established monitoring protocol for AIH.
MMF: The use of MMF for AIH is safe in most patients except during pregnancy. It is, 
however, associated with a large number of side-effects, which vary from mild, to 
tolerable to toxicity severe enough to necessitate discontinuation of treatment[6]. We 
found a 24.1% pooled adverse event rate for MMF. Previous meta-analysis estimated a 
much lower pooled adverse event rate at 14%[16]. Similar to our findings, the most 
common side-effects of MMF in AIH patients include leukopenia, which can be 
relieved by reducing the dose, and gastrointestinal issues, in the form of nausea, 
vomiting and diarrhea[34,37,40-43]. Other, less commonly reported side-effects include 
severe neutropenia, sepsis, myalgia, pancreatitis, headache, hair loss, and sore 
gums/sensitive teeth, as well as facial and upper extremity paresthesia[38,40-43]. MMF has 
major disadvantages in that it is more expensive than AZA and, most importantly, it is 
teratogenic, which is a major concern in female patients of reproductive age (since AIH 
affects mainly young females). MMF is contra-indicated during pregnancy, as the 
United State Food and Drug Administration (FDA) labels it as pregnancy category D. 
The safety of MMF during pregnancy was not addressed by any of the studies in our 
meta-analysis.
A note of caution should be added on the retrospective nature of the included 
studies, which may over- or underestimate the safety profiles of tacrolimus and MMF. 
Given the long follow-up periods reported and the observed data, both agents appear 
to be relatively safe alternatives for treating refractory AIH.
Mortality
Despite a good response to first-line treatment, the long-term mortality rate of AIH 
patients is greater than that of the general population. Untreated AIH can lead to a 
mortality rate as high as 40% within 6 mo[8,49]. We found a pooled mortality rate of 
11.5% for tacrolimus and of 9% for MMF. So far, our study is the first to evaluate the 
rate for tacrolimus as a second-line therapy in refractory AIH patients. Most of the 
included studies reported no deaths or only one dead during tacrolimus or MMF 
therapy. A previous meta-analysis underestimated the pooled mortality rate, which 
was reported as 7.2% for MMF[15]. Similar to our findings, the largest cohort to date 
related to second-line treatments in AIH[36] evaluated both tacrolimus and MMF; they 
reported the highest mortality rate of 11.2% for tacrolimus and 12.4% for MMF. 
Variation in mortality rates across individual studies may be due to a pre-selection of 
patients by referral to tertiary centers or to the exclusion of some high-risk patient 
categories[50,51]. Cohorts showing higher mortality rates have been larger, from multiple 
centers or from non-tertiary centers, and tended to report on patients who were 
younger at presentation[36].
Grading of evidence
Rating the quality of evidence by using GRADE is now becoming a recommended step 
in evidence-based synthesis and it is the most widely adopted tool for grading the 
quality of evidence and for making recommendations[52]. Previous meta-analyses that 
addressed the efficacy of tacrolimus and MMF did not include effect estimates for 
biochemical remission[15] or only provided inconclusive analysis of the effect of MMF 
as a second-line treatment[16]. Thus, they could not make comprehensive or reliable 
recommendations. Here we have assessed the evidence using GRADE, which proved 
to be of very low quality for our primary and secondary outcomes due to the risk of 
bias and inconsistency. Our analysis therefore offers a starting point for understanding 
the comprehensive evidence for using tacrolimus and MMF in refractory AIH patients, 
and our results can provide information for decision-makers, with the ultimate goal of 
improving clinical outcomes and enhancing patient care.
The natural course of AIH has been clearly outlined and the efficacy of first-line 
treatment has been well established in naive AIH, although little was known about 
second-line treatments in refractory AIH. Collectively, our results, along with earlier 
results, suggest that tacrolimus may be superior to MMF as a therapy in patients not 
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responding to first-line therapy, while MMF is considered a suitable second-line 
therapy for patients who are intolerant to the standard treatment. However, these 
results have been based on observational studies. So far, there have been no clinical 
trials comparing these treatments directly. In the absence of randomized controlled 
trials, the existing data on the efficacy of tacrolimus and MMF as second-line treatment 
modalities for AIH patients remain inconclusive; the current evidence has been mainly 
derived from several retrospective, mostly single-center, case series or reports[17,18,29-47], 
or based on expert opinion. This means the evidence is of poor quality due to 
significant levels of bias. Thus, the reproducibility of results may vary considerably 
across studies. As a consequence, the recently published guidelines[8,49], have led to 
great differences in the management of refractory AIH patients. The AASLD guideline 
states that patients with treatment failure should be managed with higher dose first-
line therapy before considering second-line treatments[8]. Whereas the European 
Association for the Study of the Liver guideline suggests using high dose first-line 
treatment or alternative medications such as MMF, 6-mercaptopurine or 6-tioguanine, 
despite reconfirmation of diagnosis and adherence[49]. These differences do not provide 
any insight into which second-line therapy to consider first for these patients, and 
emphasize the need to conduct standardized, prospective, and preferably randomized 
studies, with standardized definitions of therapeutic endpoints[53].
In summary, we found most of the evidence was of low-quality. Given the reported 
side-effects and mortality rates, we do not feel able to offer recommendations for 
future research on second-line treatment modalities for refractory AIH. More larger, 
controlled and prospective studies are required to compare alternative drugs with 
first-line treatments in patients with AIH.
Study limitations
Our study was limited by the low methodological quality and small numbers of 
patients in the studies covered by our meta-analysis.
CONCLUSION
Tacrolimus might be a promising alternative drug in the efficient treatment of AIH 
patients who did not respond to first-line treatments (it was effective in 59.1% of those 
non-responders treated as second-line), while MMF is considered effective in 73.5% of 
patients who proved to be intolerant to first-line therapy. However, we found that the 
quality of evidence is not high, and it is thus questionable whether these results should 
be worked into a clinical guideline. Well-planned, prospective, multicenter studies of 
second-line treatments for patients with AIH would help to define the optimal dose, 
treatment schedule, required duration, and treatment endpoints. In addition, such 
studies should perform close monitoring of the side-effects. Future prospects in AIH 
treatments, especially in refractory patients, will be establishing individualized 
approaches to develop more effective and better tolerated novel therapies.
ARTICLE HIGHLIGHTS
Research background
The standard treatment of autoimmune hepatitis (AIH) is based on corticosteroids, 
either given alone or in combination with azathioprine, which both lead to remission 
in 80% of patients. Second-line treatments are needed for patients who have refractory 
disease. Tacrolimus and mycophenolate mofetil (MMF) have empirically been used the 
most, as second line treatments for AIH. However, high-quality data on the alternative 
management of AIH are scarce.
Research motivation
The accumulating but still sparse data indicate that refractory AIH patients do respond 
to these second-line treatments. However, there is no firm evidence of their 
effectiveness.
Research objectives
The aims of this study were to evaluate the efficacy and safety of tacrolimus and MMF 
and the quality of evidence by using the Grading of Recommendations Assessment, 
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Development and Evaluation approach (GRADE).
Research methods
A systematic review and meta-analysis of the available data were performed. We 
reviewed the literature, focusing on our aim to identify, appraise, select and synthesize 
all the high-quality evidence available. We calculated pooled event rates for three 
outcome measures, defined as biochemical remission, adverse events, and mortality, 
with their corresponding 95% confidence intervals. Random effects model was applied 
whenever there was significant heterogeneity between studies. The GRADE approach 
was used to assess the quality of evidence for primary and secondary outcomes.
Research results
Overall, 21 observational studies, comprising 584 patients with AIH who were unable 
to tolerate or respond to first-line treatment, met our eligibility criteria. Tacrolimus is 
efficient in treating patients who did not respond to first-line treatments, yielding a 
biochemical remission rate of 59.1%, while MMF is considered effective for patients 
who are intolerant to the first-line therapy, yielding a biochemical remission rate of 
73.5%. Moreover, the overall quality assessments using GRADE proved to be very low 
for all our outcomes in both treatment groups.
Research conclusions
The available evidence shows tacrolimus and MMF are in practice considered effective 
for AIH patients who are non-responder or intolerant to first-line treatment, but we 
found no high-quality evidence to support this statement and the translation of these 
findings to AIH clinical guidelines is questionable.
Research perspectives
Well-planned, prospective, multicenter studies of second-line treatments for patients 
with AIH would help to define the optimal dose, treatment schedule, required 
duration, and treatment endpoints. In addition, such studies should perform close 
monitoring of the side-effects.
ACKNOWLEDGEMENTS
We specially thank Sijtsma K, medical information specialist at the University Medical 
Center Groningen, for help in designing the literature search strategy. We thank Senior 
J for editing the text.
REFERENCES
Ngu JH, Gearry RB, Frampton CM, Stedman CA. Mortality and the risk of malignancy in autoimmune liver 
diseases: a population-based study in Canterbury, New Zealand. Hepatology 2012; 55: 522-529 [PMID: 
21994151 DOI: 10.1002/hep.24743]
1     
Hoeroldt B, McFarlane E, Dube A, Basumani P, Karajeh M, Campbell MJ, Gleeson D. Long-term outcomes 
of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 2011; 140: 1980-
1989 [PMID: 21396370 DOI: 10.1053/j.gastro.2011.02.065]
2     
Liberal R, Krawitt EL, Vierling JM, Manns MP, Mieli-Vergani G, Vergani D. Cutting edge issues in 
autoimmune hepatitis. J Autoimmun 2016; 75: 6-19 [PMID: 27502148 DOI: 10.1016/j.jaut.2016.07.005]
3     
Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354: 54-66 [PMID: 16394302 DOI: 
10.1056/NEJMra050408]
4     
Abdollahi MR, Somi MH, Faraji E. Role of international criteria in the diagnosis of autoimmune hepatitis. 
World J Gastroenterol 2013; 19: 3629-3633 [PMID: 23801865 DOI: 10.3748/wjg.v19.i23.3629]
5     
Czaja AJ. Current and future treatments of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol 2009; 
3: 269-291 [PMID: 19485809 DOI: 10.1586/egh.09.15]
6     
Manns MP, Lohse AW, Vergani D. Autoimmune hepatitis--Update 2015. J Hepatol 2015; 62: S100-S111 
[PMID: 25920079 DOI: 10.1016/j.jhep.2015.03.005]
7     
Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM; American 
Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. 
Hepatology 2010; 51: 2193-2213 [PMID: 20513004 DOI: 10.1002/hep.23584]
8     
Peiseler M, Liebscher T, Sebode M, Zenouzi R, Hartl J, Ehlken H, Pannicke N, Weiler-Normann C, Lohse 
AW, Schramm C. Efficacy and Limitations of Budesonide as a Second-Line Treatment for Patients With 
Autoimmune Hepatitis. Clin Gastroenterol Hepatol 2018; 16: 260-267.e1 [PMID: 28126427 DOI: 
10.1016/j.cgh.2016.12.040]
9     
Dhawan A, Mieli-Vergani G. Mycophenolate mofetil--a new treatment for autoimmune hepatitis? J Hepatol 10     
Abdollahi M et al. Efficacy of second-line treatments in AIH
WJG https://www.wjgnet.com 5909 October 14, 2020 Volume 26 Issue 38
2000; 33: 480-481 [PMID: 11020006 DOI: 10.1016/s0168-8278(00)80286-x]
Jothimani D, Cramp ME, Mitchell JD, Cross TJ. Treatment of autoimmune hepatitis: a review of current 
and evolving therapies. J Gastroenterol Hepatol 2011; 26: 619-627 [PMID: 21073674 DOI: 
10.1111/j.1440-1746.2010.06579.x]
11     
Liberal R, de Boer YS, Andrade RJ, Bouma G, Dalekos GN, Floreani A, Gleeson D, Hirschfield GM, 
Invernizzi P, Lenzi M, Lohse AW, Macedo G, Milkiewicz P, Terziroli B, van Hoek B, Vierling JM, 
Heneghan MA; International Autoimmune Hepatitis Group (IAIHG). Expert clinical management of 
autoimmune hepatitis in the real world. Aliment Pharmacol Ther 2017; 45: 723-732 [PMID: 28004405 DOI: 
10.1111/apt.13907]
12     
Fallatah HI, Akbar HO. Mycophenolate mofetil as a rescue therapy for autoimmune hepatitis patients who 
are not responsive to standard therapy. Expert Rev Gastroenterol Hepatol 2011; 5: 517-522 [PMID: 
21780898 DOI: 10.1586/egh.11.45]
13     
Vierling JM. Autoimmune Hepatitis and Overlap Syndromes: Diagnosis and Management. Clin 
Gastroenterol Hepatol 2015; 13: 2088-2108 [PMID: 26284592 DOI: 10.1016/j.cgh.2015.08.012]
14     
De Lemos-Bonotto M, Valle-Tovo C, Costabeber AM, Mattos AA, Azeredo-da-Silva ALF. A systematic 
review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment. Eur J 
Gastroenterol Hepatol 2018; 30: 212-216 [PMID: 29227329 DOI: 10.1097/MEG.0000000000001019]
15     
Santiago P, Schwartz I, Tamariz L, Levy C. Systematic review with meta-analysis: mycophenolate mofetil 
as a second-line therapy for autoimmune hepatitis. Aliment Pharmacol Ther 2019; 49: 830-839 [PMID: 
30761563 DOI: 10.1111/apt.15157]
16     
Pape S, Nevens F, Verslype C, Mertens C, Drenth JPH, Tjwa ETTL. Profiling the patient with autoimmune 
hepatitis on calcineurin inhibitors: a real-world-experience. Eur J Gastroenterol Hepatol 2020; 32: 727-732 
[PMID: 31658173 DOI: 10.1097/MEG.0000000000001580]
17     
Giannakopoulos G, Verbaan H, Friis-Liby IL, Sangfelt P, Nyhlin N, Almer S; Swedish Hepatology study 
group; SweHep. Mycophenolate mofetil treatment in patients with autoimmune hepatitis failing standard 
therapy with prednisolone and azathioprine. Dig Liver Dis 2019; 51: 253-257 [PMID: 30389427 DOI: 
10.1016/j.dld.2018.10.004]
18     
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ; GRADE 
Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of 
recommendations. BMJ 2008; 336: 924-926 [PMID: 18436948 DOI: 10.1136/bmj.39489.470347.AD]
19     
Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, Montori V, Akl EA, Djulbegovic B, 
Falck-Ytter Y, Norris SL, Williams JW Jr, Atkins D, Meerpohl J, Schünemann HJ. GRADE guidelines: 4. J 
Clin Epidemiol 2011; 64: 407-415 [PMID: 21247734 DOI: 10.1016/j.jclinepi.2010.07.017]
20     
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, 
Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000; 
283: 2008-2012 [PMID: 10789670 DOI: 10.1001/jama.283.15.2008]
21     
Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M, Mowat AP, Vergani D, 
Mieli-Vergani G. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997; 25: 541-547 
[PMID: 9049195 DOI: 10.1002/hep.510250308]
22     
Floreani A, Liberal R, Vergani D, Mieli-Vergani G. Autoimmune hepatitis: Contrasts and comparisons in 
children and adults - a comprehensive review. J Autoimmun 2013; 46: 7-16 [PMID: 24035197 DOI: 
10.1016/j.jaut.2013.08.004]
23     
Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl 
J, Norris S, Guyatt GH. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011; 64: 
401-406 [PMID: 21208779 DOI: 10.1016/j.jclinepi.2010.07.015]
24     
Wan X, Wang W, Liu J, Tong T. BMC Med Res Methodol 2014; 14: 135 [PMID: 25524443 DOI: 
10.1186/1471-2288-14-135]
25     
Higgins JP, Thompson SG. Stat Med 2002; 21: 1539-1558 [PMID: 12111919 DOI: 10.1002/sim.1186]26     
Egger M, Smith GD. BMJ 1995; 311: 753-754 [PMID: 7549720 DOI: 10.1136/bmj.311.7007.753c]27     
Borenstein M, Hedges L, Higgins J, Rothstein H.  Comprehensive meta-analysis version 3. Englewood, NJ, 
USA: Biostat Inc., 2013; 104. Available from: https://www.meta-analysis.com/downloads/Meta-Analysis 
Manual V3.pdf
28     
Zolfino T, Heneghan MA, Norris S, Harrison PM, Portmann BC, McFarlane IG. Characteristics of 
autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut 2002; 50: 713-717 
[PMID: 11950822 DOI: 10.1136/gut.50.5.713]
29     
Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the 
treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004; 38: 805-809 [PMID: 
15365410 DOI: 10.1097/01.mcg.0000139050.67178.be]
30     
Chatur N, Ramji A, Bain VG, Ma MM, Marotta PJ, Ghent CN, Lilly LB, Heathcote EJ, Deschenes M, Lee 
SS, Steinbrecher UP, Yoshida EM. Transplant immunosuppressive agents in non-transplant chronic 
autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with 
mycophenolate mofetil and tacrolimus. Liver Int 2005; 25: 723-727 [PMID: 15998421 DOI: 
10.1111/j.1478-3231.2005.01107.x]
31     
Larsen FS, Vainer B, Eefsen M, Bjerring PN, Adel Hansen B. Low-dose tacrolimus ameliorates liver 
inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007; 13: 3232-
3236 [PMID: 17589903 DOI: 10.3748/wjg.v13.i23.3232]
32     
Yeoman AD, Westbrook RH, Zen Y, Maninchedda P, Portmann BC, Devlin J, O'Grady JG, Harrison PM, 
Heneghan MA. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune 
hepatitis. Hepatology 2011; 53: 926-934 [PMID: 21374663 DOI: 10.1002/hep.24141]
33     
Tannous MM, Cheng J, Muniyappa K, Farooq I, Bharara A, Kappus M, Luketic V, Stravtiz RT, Fuchs M, 
Puri P, Sanyal A, Sterling R. Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre 
experience. Aliment Pharmacol Ther 2011; 34: 405-407 [PMID: 21726256 DOI: 
10.1111/j.1365-2036.2011.04749.x]
34     
Abdollahi M et al. Efficacy of second-line treatments in AIH
WJG https://www.wjgnet.com 5910 October 14, 2020 Volume 26 Issue 38
Than NN, Wiegard C, Weiler-Normann C, Füssel K, Mann J, Hodson J, Hirschfield GM, Lohse AW, Adams 
DH, Schramm C, Oo YH. Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis 
on Tacrolimus therapy. Scand J Gastroenterol 2016; 51: 329-336 [PMID: 26458216 DOI: 
10.3109/00365521.2015.1095351]
35     
Efe C, Hagström H, Ytting H, Bhanji RA, Müller NF, Wang Q, Purnak T, Muratori L, Werner M, Marschall 
HU, Muratori P, Gunşar F, Klintman D, Parés A, Heurgué-Berlot A, Schiano TD, Cengiz M, May-Sien Tana 
M, Ma X, Montano-Loza AJ, Berg T, Verma S, Larsen FS, Ozaslan E, Heneghan MA, Yoshida EM, Wahlin 
S. Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With 
Autoimmune Hepatitis. Clin Gastroenterol Hepatol 2017; 15: 1950-1956.e1 [PMID: 28603052 DOI: 
10.1016/j.cgh.2017.06.001]
36     
Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune 
hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000; 33: 371-375 [PMID: 11019991 
DOI: 10.1016/s0168-8278(00)80271-8]
37     
Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune 
hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004; 18: 321-326 [PMID: 15152283 
DOI: 10.1155/2004/504591]
38     
Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison 
with conventional treatment for refractory disease. J Clin Gastroenterol 2005; 39: 819-825 [PMID: 
16145346 DOI: 10.1097/01.mcg.0000177260.72692.e8]
39     
Inductivo-Yu I, Adams A, Gish RG, Wakil A, Bzowej NH, Frederick RT, Bonacini M. Mycophenolate 
mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. 
Clin Gastroenterol Hepatol 2007; 5: 799-802 [PMID: 17509945 DOI: 10.1016/j.cgh.2007.02.030]
40     
Hlivko JT, Shiffman ML, Stravitz RT, Luketic VA, Sanyal AJ, Fuchs M, Sterling RK. A single center 
review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol 
Hepatol 2008; 6: 1036-1040 [PMID: 18586559 DOI: 10.1016/j.cgh.2008.04.006]
41     
Hennes EM, Oo YH, Schramm C, Denzer U, Buggisch P, Wiegard C, Kanzler S, Schuchmann M, Boecher 
W, Galle PR, Adams DH, Lohse AW. Mycophenolate mofetil as second line therapy in autoimmune 
hepatitis? Am J Gastroenterol 2008; 103: 3063-3070 [PMID: 18853972 DOI: 
10.1111/j.1572-0241.2008.02180.x]
42     
Wolf DC, Bojito L, Facciuto M, Lebovics E. Mycophenolate mofetil for autoimmune hepatitis: a single 
practice experience. Dig Dis Sci 2009; 54: 2519-2522 [PMID: 19082888 DOI: 10.1007/s10620-008-0632-0]
43     
Sharzehi K, Huang MA, Schreibman IR, Brown KA. Mycophenolate mofetil for the treatment of 
autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol 2010; 
24: 588-592 [PMID: 21037986 DOI: 10.1155/2010/891252]
44     
Baven-Pronk AM, Coenraad MJ, van Buuren HR, de Man RA, van Erpecum KJ, Lamers MM, Drenth JP, 
van den Berg AP, Beuers UH, den Ouden J, Koek GH, van Nieuwkerk CM, Bouma G, Brouwer JT, van 
Hoek B. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap 
syndromes. Aliment Pharmacol Ther 2011; 34: 335-343 [PMID: 21668459 DOI: 
10.1111/j.1365-2036.2011.04727.x]
45     
Jothimani D, Cramp ME, Cross TJ. Role of mycophenolate mofetil for the treatment of autoimmune 
hepatitis-an observational study. J Clin Exp Hepatol 2014; 4: 221-225 [PMID: 25755564 DOI: 
10.1016/j.jceh.2014.05.003]
46     
Roberts SK, Lim R, Strasser S, Nicoll A, Gazzola A, Mitchell J, Siow W, Khoo T, Hamarneh Z, Weltman 
M, Gow P, Janko N, Tse E, Mishra G, Cheng EH, Levy M, Cheng W, Sood S, Skoien R, Mitchell J, Zekry 
A, George J, MacQuillan G, Wigg A, Stuart K, Sievert W, McCaughan G; ALA Clinical Research Network. 
Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal 
Outcomes After Standard Therapy. Clin Gastroenterol Hepatol 2018; 16: 268-277 [PMID: 29050991 DOI: 
10.1016/j.cgh.2017.09.063]
47     
Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of 
organ transplantation. Drugs 2003; 63: 1247-1297 [PMID: 12790696 DOI: 
10.2165/00003495-200363120-00006]
48     
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune 
hepatitis. J Hepatol 2015; 63: 971-1004 [PMID: 26341719 DOI: 10.1016/j.jhep.2015.06.030]
49     
Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. 
Gastroenterology 1996; 110: 848-857 [PMID: 8608895 DOI: 10.1053/gast.1996.v110.pm8608895]
50     
Yoshizawa K, Matsumoto A, Ichijo T, Umemura T, Joshita S, Komatsu M, Tanaka N, Tanaka E, Ota M, 
Katsuyama Y, Kiyosawa K, Abe M, Onji M. Long-term outcome of Japanese patients with type 1 
autoimmune hepatitis. Hepatology 2012; 56: 668-676 [PMID: 22334246 DOI: 10.1002/hep.25658]
51     
Alonso-Coello P, Schünemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, Treweek S, 
Mustafa RA, Rada G, Rosenbaum S, Morelli A, Guyatt GH, Oxman AD; GRADE Working Group. GRADE 
Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed 
healthcare choices. 1: Introduction. BMJ 2016; 353: i2016 [PMID: 27353417 DOI: 10.1136/bmj.i2016]
52     
Czaja AJ. Review article: the management of autoimmune hepatitis beyond consensus guidelines. Aliment 
Pharmacol Ther 2013; 38: 343-364 [PMID: 23808490 DOI: 10.1111/apt.12381]
53     
Published by Baishideng Publishing Group Inc 
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA 
Telephone: +1-925-3991568 
E-mail: bpgoffice@wjgnet.com 
Help Desk: https://www.f6publishing.com/helpdesk 
https://www.wjgnet.com
© 2020 Baishideng Publishing Group Inc. All rights reserved.
